Latest & greatest articles for type 1 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 1 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 1 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 1 diabetes

21. Management of Type 2 Diabetes Mellitus

complications. Key points Prevention. In individuals at risk for type 2 diabetes (see Table 1), type 2 diabetes can be delayed or prevented through diet, exercise, and pharmacologic interventions [IA]. Screening. Although little evidence is available on screening for diabetes, screening should be considered every 3 years beginning at age 45 or annually at any age if BMI = 25 kg/m 2 [evidence: IID], history of hypertension [IIB], gestational diabetes [IC], or other risk factors. Diagnosis. An A1c of 6.5 (...) = generally should not be performed. Level of evidence supporting a diagnostic method or an intervention: A=randomized controlled trials; B=controlled trials, no randomization; C=observational trials; D=opinion of expert panel. 2 UMHS Management of Type 2 Diabetes Mellitus June, 2017 Table 1. Diagnosis of Diabetes: Diagnostic Tests and Glucose Values Diagnostic Test Normal Pre-diabetes Diabetes Hemoglobin A1c (A1c) a 30 mg/gm, check UA to rule out asymptomatic UTI. • Repeat spot urine ratio twice within 6

2020 University of Michigan Health System

22. Use of professional-mode flash glucose monitoring, at 3-month intervals, in adults with type 2 diabetes in general practice (GP-OSMOTIC): a pragmatic, open-label, 12-month, randomised controlled trial

, in Adults With Type 2 Diabetes in General Practice (GP-OSMOTIC): A Pragmatic, Open-Label, 12-month, Randomised Controlled Trial , , , , , , , , , , , , , , , , , , , , , , Affiliations Expand Affiliations 1 Department of General Practice, University of Melbourne, Parkville, VIC, Australia. Electronic address: j.furler@unimelb.edu.au. 2 Department of Medicine, University of Melbourne, Parkville, VIC, Australia. 3 School of Psychology, Deakin University, Geelong, VIC, Australia; Australian Centre (...) . Eligible participants were adults aged 18-80 years, with type 2 diabetes diagnosed for at least 1 year and HbA 1c at least 5·5 mmol/mol (0·5%) above their target in the past month despite being prescribed at least two non-insulin glucose-lowering drugs, insulin, or both (with therapy stable for at least 4 months). We randomly assigned participants (1:1) to either use of a professional-mode flash glucose monitoring system or usual clinical care (control). All participants wore the flash glucose

2020 EvidenceUpdates

23. Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications

Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications Prescrire IN ENGLISH - Spotlight ''Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications'', 1 January 2020 {1} {1} {1} | | > > > Dapagliflozin in type 2 diabetes: no advance in terms of cardiovascular complications Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |  (...) versus placebo included more than 17 000 patients with type 2 diabetes, half of whom were followed for at least 4 years. In this trial, dapagliflozin did not reduce the rate of cardiovascular complications of diabetes, or death. Full text available for free download. ©Prescrire 1 January 2020 Share Share Download the full review See also: Dapagliflozin. A hypoglycaemic drug causing disproportionate harm, especially to kidneys Prescrire Int 2014; 23 (147): 61-64. | | | Prescrire Your change of address

2020 Prescrire

24. Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial Full Text available with Trip Pro

, , , , , , Affiliations Expand Affiliations 1 Department of Hematology, Endocrinology and Metabolism, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan. 2 Nippon Boehringer Ingelheim Co. Ltd., Tokyo, Japan. 3 Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany. 4 Jikei University School of Medicine, Tokyo, Japan. PMID: 31692244 DOI: Item in Clipboard Efficacy and Safety of Empagliflozin as Add-On to Insulin in Japanese Patients With Type 2 Diabetes: A Randomized, Double-Blind (...) -text links Cite Abstract Aim: To assess the efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes (T2D). Materials and methods: This multicentre, double-blind, parallel-group study randomized Japanese patients with T2D insufficiently controlled with insulin (1:1:1) to empagliflozin 10 mg (n=89), empagliflozin 25 mg (n=90) or placebo (n=90) for 52 weeks. The primary endpoint was change from baseline in glycated haemoglobin (HbA1c) at 16 weeks. Results

2020 EvidenceUpdates

25. Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA1c in Andalusia (Spain): PLATEDIAN Study

Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA1c in Andalusia (Spain): PLATEDIAN Study Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA 1c in Andalusia (Spain): PLATEDIAN Study - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome (...) collection Add to an existing collection Name your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Care Actions , 43 (2), 337-342 Feb 2020 Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin

2020 EvidenceUpdates

26. Long-term Effects of Intensive Multifactorial Therapy in Individuals With Screen-Detected Type 2 Diabetes in Primary Care: 10-year Follow-Up of the ADDITION-Europe Cluster-Randomised Trial

of Intensive Multifactorial Therapy in Individuals With Screen-Detected Type 2 Diabetes in Primary Care: 10-year Follow-Up of the ADDITION-Europe Cluster-Randomised Trial Simon J Griffin et al. Lancet Diabetes Endocrinol . Dec 2019 Show details Lancet Diabetes Endocrinol Actions , 7 (12), 925-937 Authors , , , , , , , , , , , , Affiliations 1 MRC Epidemiology Unit, Institute of Metabolic Science, University of Cambridge, Cambridge, UK; Primary Care Unit, Institute of Public Health, School of Clinical (...) . Diabetologia 56 (11), 2367-2377. 2013. PMID 23959571. There were no differences in health status, well-being, quality of life and treatment satisfaction between screen-detected type 2 diabetes mellitus patients receiving int … RK Simmons et al. Health Technol Assess 20 (64), 1-86. Aug 2016. PMID 27583404. - Randomized Controlled Trial Compared with RC, IT was associated with modest increases in prescribed treatment, reduced levels of risk factors and non-significant reductions in cardiovascular events, … X

2020 EvidenceUpdates

27. A 12-week, randomized, double-blind, placebo-controlled, four-arm dose-finding phase 2 study evaluating bexagliflozin as monotherapy for adults with type 2 diabetes

Diabetes , , , , , Affiliations Expand Affiliations 1 Translational Medicine Group, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts, United States. 2 Prometrika, LLC, Cambridge, Massachusetts. PMID: 31749238 DOI: Item in Clipboard A 12-week, Randomized, Double-Blind, Placebo-Controlled, Four-Arm Dose-Finding Phase 2 Study Evaluating Bexagliflozin as Monotherapy for Adults With Type 2 Diabetes Yuan-Di Halvorsen et al. Diabetes Obes Metab . 2019 (...) Show details Diabetes Obes Metab Actions Authors , , , , , Affiliations 1 Translational Medicine Group, Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, Massachusetts, United States. 2 Prometrika, LLC, Cambridge, Massachusetts. PMID: 31749238 DOI: Item in Clipboard Full-text links Cite Abstract Aim: To compare the safety and efficacy of bexagliflozin administered as monotherapy at three dosage strengths over a 12-week period to patients with type 2 diabetes

2020 EvidenceUpdates

28. Impact of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on renal and mortality outcomes in people with Type 2 diabetes and proteinuria

your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Review Diabet Med Actions , 37 (1), 44-52 Jan 2020 Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Renal and Mortality Outcomes in People With Type 2 Diabetes and Proteinuria (...) , , , , Affiliations Expand Affiliations 1 University of Connecticut School of Pharmacy, Storrs, CT, USA. 2 College of Pharmacy at the Medical University of South Carolina, Charleston, SC, USA. 3 Janssen Scientific Affairs, LLC, Titusville, NJ, USA. PMID: 31407377 DOI: Item in Clipboard Review Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers on Renal and Mortality Outcomes in People With Type 2 Diabetes and Proteinuria C I Coleman et al. Diabet Med . Jan 2020 Show details Diabet

2020 EvidenceUpdates

29. Oral Semaglutide for Type 2 Diabetes: Effectiveness and Value

Examination Survey NMA Network meta-analysis OM1 Outcomes Model 1 OM2 Outcomes Model 2 LCD Local coverage decision LY Life year PICOTS Population, Intervention, Comparator, and Study Design PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses PRO Patient-reported outcome ©Institute for Clinical and Economic Review, 2019 Page ix Final Evidence Report – Oral Semaglutide for Type 2 Diabetes Return to Table of Contents QALY Quality-adjusted life year RCT Randomized control trial SAE (...) Summary Background In the United States (US), approximately 30 million individuals have diabetes mellitus, of whom 95% have Type 2 diabetes mellitus (T2DM). 1 Patients with diabetes have elevations in blood glucose (hyperglycemia) and are at increased risk for damage to blood vessels both large (macrovascular disease) and small (microvascular disease). Many of the complications of diabetes are the result of vascular disease, including microvascular damage to the eyes and kidneys, and macrovascular

2020 California Technology Assessment Forum

30. Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes. Full Text available with Trip Pro

Cost-Utility Analysis of Pharmaceutical Care Intervention Versus Usual Care in Management of Nigerian Patients with Type 2 Diabetes. To assess the cost-effectiveness of pharmaceutical care (PC) intervention versus usual care (UC) in the management of type 2 diabetes.This study was a randomized, controlled study with a 12-month patient follow-up in two Nigerian tertiary hospitals. One hundred and ten patients were randomly assigned to each of the "intervention" (PC) and the "control" (UC) groups (...) , respectively, with an associated incremental cost-utility ratio of NGN 88,525 ($571) per QALY gained. In the cost-effectiveness acceptability curve, the probability that PC was more cost-effective than UC was 95% at the NGN 250,000 ($1613) per QALY gained threshold and 52% at the NGN 88,600 ($572) per QALY gained threshold.The PC intervention was very cost-effective among patients with type 2 diabetes at the NGN 88,525 ($571.13) per QALY gained threshold, although considerable uncertainty surrounds

2019 Value in health regional issues Controlled trial quality: uncertain

31. Effect of yoga and aerobics exercise on sleep quality in women with Type 2 diabetes: a randomized controlled trial. Full Text available with Trip Pro

Effect of yoga and aerobics exercise on sleep quality in women with Type 2 diabetes: a randomized controlled trial. The aim of this study was investigating the effect of 12 weeks of yoga and aerobic exercise (running on a treadmill) on the sleep quality in women with Type 2 diabetes.39 diabetic women were selected from Semnan city with the mean age of 46.85±3.35 years, weight of 69.79±17.18 kg, height of 155.03±5.00, BMI of 29.64±5.00 kg/m2 who had a background of diabetes for 6.46±2.69 years (...) of aerobic exercise in women suffering from diabetes Type 2. Thus, yoga exercise can be suggested to these patients.

2019 Sleep science (Sao Paulo, Brazil) Controlled trial quality: uncertain

32. The Impact of Pharmaceutical Care Intervention on the Quality of Life of Nigerian Patients Receiving Treatment for Type 2 Diabetes. Full Text available with Trip Pro

The Impact of Pharmaceutical Care Intervention on the Quality of Life of Nigerian Patients Receiving Treatment for Type 2 Diabetes. To evaluate the impact of pharmaceutical care (PC) intervention on health-related quality of life (HRQOL) of patients with type 2 diabetes.This study was a randomized, controlled study with a 12-month patient follow-up. The study protocol was approved by the Research Ethical Committees of the institutions in which this study was conducted. A total of 110 patients (...) or Mann-Whitney U tests for nonnormally distributed data at baseline, 6 months, and 12 months. Comparisons of proportions were done by using the chi-square test.The overall HRQOL (0.86 ± 0.12 vs. 0.64 ± 0.10; P < 0.0001) and single attributes except "hearing" functioning of the patients were significantly improved at 12 months in the PC intervention arm when compared with the UC arm. The HRQOL utility score was highly negatively (deficit ≥10%) associated with increasing age (≥52 years), diabetes

2019 Value in health regional issues Controlled trial quality: uncertain

33. Metformin hydrochloride / saxagliptin / dapagliflozin (Qtrilmet) - type 2 diabetes

Metformin hydrochloride / saxagliptin / dapagliflozin (Qtrilmet) - type 2 diabetes Official address Domenico Scarlattilaan 6 ? 1083 HS Amsterdam ? The Netherlands An agency of the European Union Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 © European Medicines Agency, 2019. Reproduction is authorised provided the source is acknowledged. EMA/521799/2019 EMEA/H/C/004910 Qtrilmet (...) (metformin / saxagliptin / dapagliflozin) An overview of Qtrilmet and why it is authorised in the EU What is Qtrilmet and what is it used for? Qtrilmet is a diabetes medicine that contains the active substances metformin, saxagliptin and dapagliflozin. It is used to treat type 2 diabetes in: • adults whose blood sugar is not controlled well enough with metformin combined with either saxagliptin or dapagliflozin (including those also taking a sulphonylurea, another type of diabetes medicine); • adults who

2019 European Medicines Agency - EPARs

34. Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial

of Clinical Medicine, University of Oslo, Norway. Electronic address: joran.hjelmeseth@siv.no. PMID: 31678062 DOI: Item in Clipboard Gastric Bypass Versus Sleeve Gastrectomy in Patients With Type 2 Diabetes (Oseberg): A Single-Centre, Triple-Blind, Randomised Controlled Trial Dag Hofsø et al. Lancet Diabetes Endocrinol . Dec 2019 Show details Lancet Diabetes Endocrinol Actions , 7 (12), 912-924 Authors , , , , , , , , , , , , , , Affiliations 1 Morbid Obesity Centre, Vestfold Hospital Trust, Tønsberg (...) of diabetes and β-cell function. Methods: We conducted a single-centre, triple-blind, randomised trial at Vestfold Hospital Trust (Tønsberg, Norway), in which patients (aged ≥18 years) with type 2 diabetes and obesity were randomly assigned (1:1) to receive gastric bypass or sleeve gastrectomy (the Oseberg study). Randomisation was performed with a computerised random number generator and a block size of 10. Treatment allocation was masked from participants, study personnel, and outcome assessors

2019 EvidenceUpdates

35. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial Full Text available with Trip Pro

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral semaglutide and the sodium-glucose cotransporter 2 inhibitor empagliflozin were compared in patients with type 2 diabetes uncontrolled on metformin.Patients were randomized to once-daily open-label treatment with oral semaglutide 14 mg (n = 412) or empagliflozin 25 mg (n = 410) in a 52-week trial. Key end (...) at week 26 (treatment policy), but oral semaglutide was significantly better than empagliflozin at week 52 (trial product -4.7 vs. -3.8 kg; P = 0.0114). Gastrointestinal adverse events were more common with oral semaglutide.Oral semaglutide was superior to empagliflozin in reducing HbA1c but not body weight at 26 weeks in patients with type 2 diabetes uncontrolled on metformin. At week 52, HbA1c and body weight (trial product estimand) were significantly reduced versus empagliflozin. Oral semaglutide

2019 EvidenceUpdates

36. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial Full Text available with Trip Pro

. 7.1% with placebo; mostly mild to moderate).Oral semaglutide was superior to placebo in reducing HbA1c and body weight when added to insulin with or without metformin in patients with type 2 diabetes. The safety profile was consistent with other glucagon-like peptide 1 receptor agonists.© 2019 by the American Diabetes Association. (...) Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial To investigate the efficacy, safety, and tolerability of oral semaglutide added to insulin with or without metformin.Patients with type 2 diabetes uncontrolled on insulin with or without metformin were randomized to oral semaglutide 3 mg (N = 184), 7 mg (N = 182), or 14 mg (N = 181) or to placebo (N = 184) in a 52-week, double

2019 EvidenceUpdates

37. Comparative cardiovascular and hypoglycaemic safety of glimepiride in type 2 diabetes: A population-based cohort study Full Text available with Trip Pro

: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation Diabetes Obes Metab Actions , 22 (2), 254-262 Feb 2020 Comparative Cardiovascular and Hypoglycaemic Safety of Glimepiride in Type 2 Diabetes: A Population-Based Cohort Study , , , Affiliations Expand Affiliations 1 Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital (...) University, Montreal, Quebec, Canada. PMID: 31596043 DOI: Item in Clipboard Comparative Cardiovascular and Hypoglycaemic Safety of Glimepiride in Type 2 Diabetes: A Population-Based Cohort Study Antonios Douros et al. Diabetes Obes Metab . Feb 2020 Show details Diabetes Obes Metab Actions , 22 (2), 254-262 Authors , , , Affiliations 1 Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada. 2 Department of Epidemiology, Biostatistics and Occupational

2019 EvidenceUpdates

38. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial (Abstract)

Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial SGLT2 (sodium-glucose cotransporter 2) inhibitors lower cardiovascular events in type 2 diabetes mellitus but whether they promote direct cardiac effects remains unknown. We sought to determine if empagliflozin causes a decrease in left ventricular (LV) mass in people with type 2 diabetes mellitus and coronary artery (...) measures included 6-month changes in LV end-diastolic and -systolic volumes indexed to body surface area, ejection fraction, 24-hour ambulatory blood pressure, hematocrit, and NT-proBNP (N-terminal pro b-type natriuretic peptide).Among the 97 participants (90 men [93%], mean [standard deviation] age 62.8 [9.0] years, type 2 diabetes mellitus duration 11.0 [8.2] years, estimated glomerular filtration rate 88.4 [16.9] mL/min/1.73m2, LV mass indexed to body surface area 60.7 [11.9] g/m2), 90 had evaluable

2019 EvidenceUpdates

39. Remission of type 2 diabetes: a position statement from the Association of British Clinical Diabetologists (ABCD) and the Primary Care Diabetes Society (PCDS)

Gregg EW, Chen H, Wagenknecht LE, et al. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA 2012; 308:2489–96. https://doi.org/10.1001/jama.2012.67929 Wing RR, Phelan S. Long-term weight loss maintenance. Am J Clin Nutr 2005;82(1 Suppl):222S–5S. https://doi.org/10.1093/ajcn/82.1.222S Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet 2018;391:541–51 (...) Remission of type 2 diabetes: a position statement from the Association of British Clinical Diabetologists (ABCD) and the Primary Care Diabetes Society (PCDS) Remission of type 2 diabetes: a position statement from the Association of British Clinical Diabetologists (ABCD) and the Primary Care Diabetes Society (PCDS) | Nagi | British Journal of Diabetes Font Size User Username Password Remember me Click for EXTOD PEAK 2019 Conference 18th October 2019, Glasgow ABCD Autumn Meeting 2019 28 / 29

2019 Association of British Clinical Diabetologists

40. Type 2 Diabetes Mellitus and Heart Failure Full Text available with Trip Pro

-1 receptor agonists if no recent HF decompensation) could be considered, but use with caution; may require dose adjustment DM indicates diabetes mellitus; DPP-4, dipeptidyl peptidase-4; EF, ejection fraction; eGFR, estimated glomerular filtration rate; GLP-1, glucagon-like peptide-1; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; SGLT-2, sodium glucose cotransporter type 2; and TZDs, thiazolidinedione drugs. Figure 3 (...) with either GLP-1 receptor agonists or DPP-4 inhibitors compared with other glucose-lowering therapies. Additional data are still needed to determine whether there is, in fact, a higher risk of HF with DPP-4 inhibitors in individuals with DM. Some additional information could come from the CARMELINA trial (Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus; URL: . Unique identifier: NCT01897532), which compares linagliptin versus placebo

2019 American Heart Association